Servier has entered into an agreement with Kaerus Bioscience, a UK-based biotechnology company co-founded by Medicxi, to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS). Financial details include an upfront payment, with development and commercial earn-outs that could bring the total value of the deal to $450 million.
